^
    Back
    Association details:
    Biomarker:EGFR-SEC61G fusion + EGFR amplification
    Cancer:Non Small Cell Lung Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    gefitinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    The Oncologist
    Title:

    Gefitinib combined with cetuximab for the treatment of lung adenocarcinoma harboring the EGFR-IGR (SEC61G) fusion and EGFR amplification

    Published date:
    08/03/2021
    Excerpt:
    ...clinical evidence that combined targeted therapy with gefitinib and cetuximab could result in a significant antitumor response in patients with the EGFR-IGR fusion and EGFR amplification.
    DOI:
    https://doi.org/10.1002/onco.13921